Within the field of neurodegeneration, we specialize in the treatment and research of Dementia and Parkinson’s Disease. Our dedicated team focuses on these specific conditions, utilizing the latest scientific advancements and methodologies. Our commitment to excellence and innovation continues to drive our research forward, offering hope and new possibilities to those affected by these challenging conditions.
We’re committed to advancing the understanding and treatment of Dementia through pioneering clinical trials and cutting-edge research. Specializing in this complex neurodegenerative condition, we are dedicated to developing innovative therapies aimed at improving patient outcomes and quality of life. Join us in our mission to push forward the frontiers of Dementia research, striving to offer new hope and effective treatments to individuals affected by this challenging condition.
Read moreAt Julius Clinical we lead neurodegenerative disease treatments through advanced clinical trials, collaborating with experts and using cutting-edge methods to develop innovative therapies for better patient outcomes amidst nerve cell deterioration and related neurological issues.
Read moreWe’re committed to advancing the understanding and treatment of Dementia through pioneering clinical trials and cutting-edge research. Specializing in this complex neurodegenerative condition, we are dedicated to developing innovative therapies aimed at improving patient outcomes and quality of life. Join us in our mission to push forward the frontiers of Dementia research, striving to offer new hope and effective treatments to individuals affected by this challenging condition.
Read moreAt Julius Clinical we lead neurodegenerative disease treatments through advanced clinical trials, collaborating with experts and using cutting-edge methods to develop innovative therapies for better patient outcomes amidst nerve cell deterioration and related neurological issues.
Read moreLIVE WEBINAR | NOVEMBER 26 - 2024 | 17.00 CET Time to event trial designs in ALS: How useful are they? During the webinar hosted by Lieza Exalto, Ruben van Eijk, Lotte Smets and Jordi van Unnik will touch upon:An introduction to event-driv...
On the 27th of June, we organized the webinar: 'Clinical Consequences of the New MASLD Nomenclature' with guest speaker Prof. Maja Thiele.During this webinar, our speaker and hosts dived into the following topics:Is the MASLD nomeclature...
On October 15, at 16.00 CEST, we presented the webinar:Plasma biomarkers for diagnosis and monitoring of neurodegenerative disordersTopics that are discussed:Plasma biomarkers, such as Amyloid, pTau and NfL. Treatment effect in ne...
Explore our Neurodegeneration trial capabilities, case studies, and other resources.
"*" indicates required fields
"*" indicates required fields
